Paulozzi LJ, et al. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines--United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63:562-568.
Centers for Disease Control and Prevention. US opioid dispensing maps. Last reviewed December 7, 2020. Accessed August 13, 2021. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html
Bell TJ, et al. The prevalence, severity and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey. (PROBE 1). Pain Med. 2009;10:35-42.
Abramowitz L, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013;16:1423-33.
Kalso E, et al. Opioids in chronic, non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-380.
Camilleri M, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroent Motil. 2014;26:1386-1395.
Lacy BE, et al. Bowel disorders. Gastroenterology. 2016;150:1393-1407.
Rome IV diagnostic criteria for opioid-induced constipation. Accessed September 7, 2021. https://www.mdcalc.com/rome-iv-diagnostic-criteria-opioid-induced-constipation
Brenner DM, et al. Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep. 2017;19:1-6.
Chou R, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
National Comprehensive Cancer Network (NCCN). Adult cancer pain (V2. 2021). Accessed September 7, 2021. http://www.nccn.org/professionals/physician_gls/pain.pdf
Argoff CE, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16:2324-2337.
Crockett SD, et al. American Gastroenterological Association Institute Guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156:218-226.
Fumita S, et al. Patients' self-assessment of the symptoms and impact of opioid-induced constipation: results from a prospective observational cohort study of Japanese patients with cancer. J Pain Symptom Manage. 2020;59(:1043-1051.e2.
Candy B, et al. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015;5:CD003448.
Emmanuel A, et al. Laxatives do not improve symptoms of opioid-induced constipation; results of a patient survey. Pain Med. 2017;18:1932-1940.
Pergolizzi JV, et al. The use of peripheral µ-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety. Drug Des Develop Ther. 2020;14:1009-1025.
Becker G, et al. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. 2009;373:1198–206.
Michna E, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12:554-562.
Rauck R, et al. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract. 2017;17:820-828.
Methylnaltrexone [prescribing information]. Approved 2008. Revised April 2020.
Naloxegol [prescribing information]. Approved 2014. Revised April 2020.
Naldemedine [prescribing information]. Approved 2017. Revised May 2020.
Webster L, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154:1542-1550.
Chey WD, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387-2396.
Webster LR, et al. A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2017;18:2350-2360.
Hale M, et al. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017;2:555-564.
Webster LR, et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018;159:987-994.
Holzer P. A pharmacology of opioids and their effects on gastrointestinal function. J Gastroenterol Suppl. 2014;2:9-16.
Nee J, et al. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1569-1584.
Brenner DM, et al. Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic non-cancer pain syndromes from a phase 2 randomized study. 2020;161:1027-1036.
Sloots CEJ, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55:2912-2921.
Alvaro D, et al. What to do and what not to do in the management of opioid-induced constipation: a choosing wisely report. Pain Ther. 2020;9:657-667.
Suares NC, et al. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33:895–901.
Müller-Lissner SA, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100:232-242.
Rentz AM, et al. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12:371-383.
Rentz AM, et al. Observational, non-intervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin. 2011;27:35-44.
Lubiprostone [prescribing information]. Approved 2006. Revised November 2012.
Plecanatide [prescribing information]. Approved 2017. Revised April 2021.
Linaclotide [prescribing information]. Approved 2012. Revised August 2021.
LoCasale RJ, et al. The burden of opioid-induced constipation: Discordance between patient and health care provider reports. J Manag Care Spec Pharm. 2016;22:236-45.
Streicher JM, et al. Peripherally acting µ-opioid receptor antagonists for the treatment of opioid-related side effects: mechanism of action and clinical implications. J Pharm Pract. 2018;31:658-669.
Andresen V, et al. United European Gastroenterol J. 2018;6:1254-1266.
Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106:835-842.
Frantsve LME, et al. Patient-provider interactions in the management of chronic pain: current findings within the context of shared medical decision making. Pain Medicine. 2007;8:25-35.
Buetow S. The scope for the involvement of patients in their consultations with health professionals: Rights, responsibilities and preferences of patients. J Med Ethics. 1998;24:243-247.
Simmons LA, et al. Patient engagement as a risk factor in personalized health care: a systematic review of the literature on chronic disease. Genome Med. 2014;6:16.
Huang TT, et al. Individualized programme to promote self-care among older adults with asthma: Randomized controlled trial. J Adv Nurs. 2009;65:348-358.
Coyne KS, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clincoecon Outcomes Res. 2014;6:269-281.
Argoff CE. Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting µ-opioid receptor antagonists. Clin J Pain. 2020;36:716-722.

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Brooks D. Cash, MD, AGAF, FACG, FASGE

Chief, Division of Gastroenterology, Hepatology, and Nutrition
Dan and Lillie Sterling Professor of Medicine
UT Health McGovern Medical School
Houston, Texas

Disclosures

Disclosure: Brooks D. Cash, MD, AGAF, FACG, FASGE, has the following relevant financial relationships:
Advisor or consultant for: AbbVie Inc.; Redhill
Speaker or a member of a speakers bureau for: AbbVie Inc.; Redhill

Joel J. Heidelbaugh, MD

Clinical Professor
Department of Family Medicine
University of Michigan Medical School
Ann Arbor, Michigan

Disclosures

Disclosure: Joel J. Heidelbaugh, MD, has no relevant financial relationships.

Kimberly Orleck, PA-C, MPH, RD

APP Supervisor
Atlanta Gastroenterology Associates
Atlanta, Georgia

Disclosures

Disclosure: Kimberly Orleck, PA-C, MPH, RD, has the following relevant financial relationships:
Advisor or consultant for: AbbVie Inc.; Bristol Myers Squibb Company; Lilly; Phanthom Pharmaceuticals; Salix Pharmaceuticals
Speaker or a member of a speakers bureau for: AbbVie Inc.; Bristol Myers Squibb Company; Salix Pharmaceuticals

Editor

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

CME/CE Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

CME/CE Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Concepts and Cases in Managing Opioid-Induced Constipation

Authors: Brooks D. Cash, MD, AGAF, FACG, FASGE; Joel J. Heidelbaugh, MD; Kimberly Orleck, PA-C, MPH, RD
CME / ABIM MOC / CE Released: 10/7/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/7/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for gastroenterologists, primary care physicians (PCPs), pain specialists, nurses, nurse practitioners (NPs), physician assistants (PAs), and others who diagnose and treat patients with opioid-induced constipation (OIC).

The goal of this activity is to improve clinicians’ knowledge and competence regarding the diagnosis and management of OIC, including team-based care, to improve patient outcomes.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Team-based roles in counseling patients regarding risk for OIC
- Evidence-based treatment options for OIC
Have greater competence related to
- Tailoring treatments according to presentation of OIC

Disclosures

Faculty

Brooks D. Cash, MD, AGAF, FACG, FASGE

Chief, Division of Gastroenterology, Hepatology, and Nutrition
Dan and Lillie Sterling Professor of Medicine
UT Health McGovern Medical School
Houston, Texas

Disclosures

Disclosure: Brooks D. Cash, MD, AGAF, FACG, FASGE, has the following relevant financial relationships:
Advisor or consultant for: AbbVie Inc.; Redhill
Speaker or a member of a speakers bureau for: AbbVie Inc.; Redhill

Joel J. Heidelbaugh, MD

Clinical Professor
Department of Family Medicine
University of Michigan Medical School
Ann Arbor, Michigan

Disclosures

Disclosure: Joel J. Heidelbaugh, MD, has no relevant financial relationships.

Kimberly Orleck, PA-C, MPH, RD

APP Supervisor
Atlanta Gastroenterology Associates
Atlanta, Georgia

Disclosures

Disclosure: Kimberly Orleck, PA-C, MPH, RD, has the following relevant financial relationships:
Advisor or consultant for: AbbVie Inc.; Bristol Myers Squibb Company; Lilly; Phanthom Pharmaceuticals; Salix Pharmaceuticals
Speaker or a member of a speakers bureau for: AbbVie Inc.; Bristol Myers Squibb Company; Salix Pharmaceuticals

Editor

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

CME/CE Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

CME/CE Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

Contact This Provider

For Physician Assistants

Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 10/7/2022. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Gastroenterology

CME / ABIM MOC / CE

Concepts and Cases in Managing Opioid-Induced Constipation

Authors: Brooks D. Cash, MD, AGAF, FACG, FASGE; Joel J. Heidelbaugh, MD; Kimberly Orleck, PA-C, MPH, RDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 10/7/2021

Valid for credit through: 10/7/2022, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Best Practices in Guideline-Based Management of Opioid-Induced Constipation

Dr Cash reviews best practices and guidelines for opioid-induced constipation (OIC) treatment in the clinic.
Brooks D. Cash, MD, AGAF, FACG, FASGE

Patient Cases in Opioid-Induced Constipation

Patient cases illustrate evidence-based management of OIC and opioid-exacerbated constipation (OEC).
Joel J. Heidelbaugh, MD

Patient-Centric Care in Opioid-Induced Constipation Management

Team-based care in OIC is reviewed.
Kimberly Orleck, PA-C, MPH, RD

Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 6

CME / ABIM MOC / CE Information

Print
Like Tweet

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Brooks D. Cash, MD, AGAF, FACG, FASGE

Joel J. Heidelbaugh, MD

Kimberly Orleck, PA-C, MPH, RD

Editor

Roderick Smith, MS

CME/CE Reviewer

Esther Nyarko, PharmD

CME/CE Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Concepts and Cases in Managing Opioid-Induced Constipation

Target Audience and Goal Statement

Disclosures

Faculty

Brooks D. Cash, MD, AGAF, FACG, FASGE

Joel J. Heidelbaugh, MD

Kimberly Orleck, PA-C, MPH, RD

Editor

Roderick Smith, MS

CME/CE Reviewer

Esther Nyarko, PharmD

CME/CE Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Physician Assistants

Instructions for Participation and Credit

Concepts and Cases in Managing Opioid-Induced Constipation

Contents of This CME Activity

Best Practices in Guideline-Based Management of Opioid-Induced Constipation

Patient Cases in Opioid-Induced Constipation

Patient-Centric Care in Opioid-Induced Constipation Management

Assessment Survey